{"schema_version":"secwatch.filing_event.v1","accession":"0001773427-24-000016","form_type":"8-K","ticker":null,"cik":"0001773427","company_name":"SpringWorks Therapeutics, Inc.","filed_at":"2024-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.006506+00:00","generated_at":"2026-06-03T00:45:43.915431+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"SpringWorks Q1 OGSIVEO revenue $21M; net loss widens to $87.4M","bullets":["OGSIVEO net product revenue $21.0M in first full quarter of U.S. launch.","Net loss $87.4M ($1.18 per share) vs. $73.4M ($1.18 per share) in Q1 2023, driven by higher SG&A and R&D costs.","Cash, equivalents and marketable securities $573.0M as of March 31, 2024.","EMA validated MAA for nirogacestat in desmoid tumors; rolling NDA submission for mirdametinib in NF1-PN initiated.","Phase 2b ReNeu trial results accepted for oral presentation at 2024 ASCO Annual Meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001773427-24-000016","json":"https://secwatch.observer/filing/0001773427-24-000016.json","markdown":"https://secwatch.observer/filing/0001773427-24-000016.md","text":"https://secwatch.observer/filing/0001773427-24-000016.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1773427/000177342724000016/0001773427-24-000016-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1773427/000177342724000016/swtx-20240502.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T00:45:43.915431+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"460e66836a22596c191a8511f9064feb22823a94","claim":"SpringWorks Therapeutics, Inc. reported the quarter ended March 31, 2024 results: revenue $21.0 million, net income $87.4 million, EPS $1.18 per share.","evidence_excerpt":"reference in such filing. --- EX-99.1 (EX-99.1) --- SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates – Achieved $21.0 million in OGSIVEO ® (nirogacestat) net product revenue in the first quarter – – Received validation from the EMA for MAA of nirogacestat for the treatment of adults with desmoid tumors","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1773427/000177342724000016/0001773427-24-000016-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Revenue","value":"$21.0 million"},{"label":"Net income","value":"$87.4 million"},{"label":"EPS","value":"$1.18 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}